Michael King
Stock Analyst at EF Hutton
(0.90)
# 3,972
Out of 5,124 analysts
107
Total ratings
37.17%
Success rate
-10.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $19.25 | +3,276.62% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $2.64 | +316.67% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.22 | +2,522.95% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $1.35 | +4,974.07% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $11.27 | +1,674.62% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.61 | +1,255.77% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $785.51 | +9.74% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $43.90 | -45.33% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $2.94 | +5,546.26% | 8 | Mar 28, 2023 | |
| XNCR Xencor | Reiterates: Buy | $42 | $11.61 | +261.76% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $328.16 | -7.36% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $12.28 | +844.63% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.52 | +57.98% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $47.62 | -49.60% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $49.73 | -7.50% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $26.53 | +261.85% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.54 | +6,555.57% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $37.08 | -16.40% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $811.45 | -95.56% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $19.25
Upside: +3,276.62%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $2.64
Upside: +316.67%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.22
Upside: +2,522.95%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $1.35
Upside: +4,974.07%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $11.27
Upside: +1,674.62%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.61
Upside: +1,255.77%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $785.51
Upside: +9.74%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $43.90
Upside: -45.33%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $2.94
Upside: +5,546.26%
Xencor
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $11.61
Upside: +261.76%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $328.16
Upside: -7.36%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $12.28
Upside: +844.63%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $6.52
Upside: +57.98%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $47.62
Upside: -49.60%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $49.73
Upside: -7.50%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $26.53
Upside: +261.85%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.54
Upside: +6,555.57%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $37.08
Upside: -16.40%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $811.45
Upside: -95.56%